112 results
8-K
EX-10.1
LXRX
Lexicon Pharmaceuticals Inc
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law; or (iii … Privacy Law.
(v) Litigation. There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now
8-K
EX-1.1
LXRX
Lexicon Pharmaceuticals Inc
29 Dec 23
Entry into a Material Definitive Agreement
5:29pm
. Except as otherwise disclosed in the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any legal … in a Material Adverse Change; (D) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation
S-8
EX-5.1
LXRX
Lexicon Pharmaceuticals Inc
4 Aug 23
Registration of securities for employees
7:09am
of this opinion. As to any facts material to our opinions, we have made no independent investigation or verification of such facts and have relied, to the extent
8-K
EX-1.1
kui vmycg
2 Jun 23
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
4:31pm
8-K
EX-1.1
df4x1653e me
29 Jul 22
Lexicon Announces Proposed Public Offering of Common Stock
5:18pm
S-8
EX-5.1
u7lgc
6 Aug 21
Registration of securities for employees
4:14pm
8-K
EX-10.1
8lkkvxn4dp
12 Feb 21
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
ofk9bc
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
8-K
EX-10.2
u861r7 kot9s5w6
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
8-K
EX-10.1
f7yv4l58oz4
22 Oct 20
Entry into a Material Definitive Agreement
7:12am
8-K
EX-2.1
kw02f
11 Sep 20
Lexicon Pharmaceuticals Completes the Sale of Xermelo to
4:11pm